Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of Crohn's disease (CD) for at least 3 months prior to Baseline.
* Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.
* Confirmed diagnosis of moderate to severe Crohn's Disease as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic score for CD (SES-CD).
* Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies.

Exclusion Criteria:

* Current diagnosis of ulcerative colitis or indeterminate colitis.
* Receipt of CD approved biologic agents prior to Baseline (as detailed in protocol), or any investigational biologic or other agent or procedure prior to Baseline (as detailed in protocol).
* Prior exposure to p19 and/or p40 inhibitors (e.g., risankizumab and ustekinumab).
* Currently know complications of CD (strictures, short bowel, etc).

Where it's running

• Advanced Gastroenterology, P.C /ID# 224396
  Chandler, Arizona, United States
• Southern California Res. Ctr. /ID# 223484
  Coronado, California, United States
• Hoag Memorial Hosp Presbyterian /ID# 224373
  Irvine, California, United States
• United Medical Doctors /ID# 223486
  Los Alamitos, California, United States
• TLC Clinical Research Inc /ID# 223467
  Los Angeles, California, United States
• Duplicate_UC Davis Medical Center /ID# 225700
  Sacramento, California, United States

+250 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Abbvie INC. — AbbVie

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• Switching to ustekinumab for kids with Crohn's or ulcerative colitis who developed psoriasis after anti-TNF therapy

  This study tests whether switching to ustekinumab helps children with inflammatory bowel disease who developed psoriasis while on anti-TNF drugs.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, France · NCT07529236

• Guselkumab versus risankizumab for moderate-to-severe Crohn's disease

  This comparison tests whether guselkumab or risankizumab works better to reduce intestinal inflammation in people with moderately to severely active Crohn's disease.

  Recruiting at 162 sites Phase 3 Janssen Research & Development, LLC · Dothan, Alabama and 163 other locations · NCT07499232

• Guselkumab for adults with Crohn's disease after ustekinumab failure

  This study will try guselkumab for adults with moderate to severe Crohn's disease who did not respond to or could not tolerate ustekinumab to see if they reach remission after 52 weeks.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07487480

• How risankizumab moves through the body after IV vs SC dosing in healthy adults

  This study tests how risankizumab behaves in the body after intravenous and subcutaneous doses in healthy adult volunteers.

  Recruiting at 2 sites Phase 1 AbbVie · Anaheim, California and 1 other locations · NCT07466550

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.